Media Releases and Opportunities
» Go to news mainMedia opportunity: New Dalhousie University study finds opioid agonist treatment reduces risk of death and rehospitalisation among people who inject drugs
A team of scientists led by Dalhousie University along with researchers in Australia and the United Kingdom has found that opioid agonist treatment, or OAT, can lower the risk of death and recurrent infections linked to injection drug use following hospitalisation.
Opioid agonist treatment, which involves medications like methadone and buprenorphine, prevents opioid withdrawal symptoms and allows people to reduce or avoid the use of illegal opioids, like heroin or fentanyl. OAT has been shown to be highly effective at reducing overdose deaths, HIV and hepatitis C virus infections, but there has been little research on whether the treatment prevents recurrent bacterial infections after patients leave the hospital.
Dr. Thomas Brothers, a general internal medicine resident at Dalhousie, led the study with Australia's National Drug and Alcohol Research Centre, or NDARC. The team identified 8,940 people with opioid use disorder who were admitted to hospitals in New South Wales between 2001 and 2018 with injecting-related infections, including skin and soft-tissue infection, sepsis, endocarditis, septic arthritis, and brain or spine abscesses.
In the new paper in PLOS Medicine, the researchers outline how the use of the treatment after discharge resulted in fewer re-hospitalisations for injecting-related infections and fewer deaths. Dr. Brothers and colleagues conclude that hospitals should facilitate access to OAT for patients with injecting-related infections, an issue he assessed in an earlier study that looked at the provision of the treatment in hospitals in the Maritimes.
Dr. Brothers, who is also a NDARC Visiting Fellow and a PhD student at University College London, is available to discuss the findings and how OAT should be considered as part of a treatment strategy for injecting-related infections as well as other health risks, like HIV and hepatitis C.
-30-
Media contacts:
Alison Auld
Senior Research Reporter
Communications, Marketing & Creative Services
Dalhousie University
Cell: 902-220-0491
Email: Alison.auld@dal.ca
NDARC
Email: ndarc.media@unsw.edu.au
Recent News
- Media opportunity: Being involved in extracurricular activities really does matter when it comes to 'mattering': Dalhousie University research
- Media opportunity: Podcast by Dalhousie researcher and Halifax photographer looks at barriers to Nova Scotia's coastline, decreasing access to waterfronts and problems with litter, marine debris in public coastal areas
- Media opportunity: Dalhousie University researcher pioneers new cancer treatment ‑‑ cutting‑edge CAR‑T cell therapy
- Media opportunity: Research sheds light on the difficulty temporary foreign workers can face in securing permanent residency in P.E.I.
- Media opportunity: World's largest stores of unfrozen freshwater projected to warm and affect cold‑water habitats, geothermal energy resources and drinking water quality : Dalhousie University research
- Media release: Dalhousie University research reveals conservation benefits are doubled for reef sharks and rays in fully protected marine areas that also have strong fisheries management
- Media release: New program partners Dalhousie researcher and IWK Health to tackle violence against women
- Media opportunity: Dalhousie University researchers and an international team identify new strain of mpox virus in Africa that can spread through heterosexual sex and community contact
Comments
comments powered by Disqus